{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:18:35Z","timestamp":1771885115630,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The physical compatibility of telavancin with select i.v. drugs during simulated Y-site administration was evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Telavancin for injection was reconstituted according to manufacturer\u2019s recommendations and diluted with 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer\u2019s injection to a concentration of 7.5 mg\/mL. A Y site was simulated in culture tubes by mixing 5 mL of telavancin solution with 5 mL of a tested drug solution and then switching the order of drug mixing. All mixtures were prepared in duplicate and stored at room temperature. Solutions were inspected for visual, turbidity, and pH changes immediately after preparation and 15, 60, and 120 minutes after preparation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 52 drugs tested, telavancin was physically compatible with 39 drugs in all test solutions. Telavancin was incompatible with amphotericin B deoxycholate, liposomal amphotericin B, digoxin, esomeprazole sodium, furosemide, levofloxacin, and micafungin sodium in all diluents. Colistimethate sodium, cyclosporine, heparin sodium, imipenem\u2013cilastatin sodium, methylprednisolone sodium succinate, and propofol were incompatible with telavancin in specific diluents. Incompatibilities included precipitation, positive Tyndall beam test, and increases in turbidity. There were no substantial changes in pH over the 120-minute study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Telavancin 7.5 mg\/mL in 0.9% sodium chloride injection, 5% dextrose injection, and lactated Ringer\u2019s injection was found to be physically compatible for 120 minutes at room temperature with 39 of the 52 drugs tested during simulated Y-site administration. Seven drugs were incompatible in all diluents, and 6 were incompatible in at least one diluent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2146\/ajhp100663","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T19:54:56Z","timestamp":1321559696000},"page":"2265-2270","source":"Crossref","is-referenced-by-count":14,"title":["Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration"],"prefix":"10.1093","volume":"68","author":[{"given":"Seth T.","family":"Housman","sequence":"first","affiliation":[{"name":"Clinical and Economic Studies, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela R.","family":"Tessier","sequence":"additional","affiliation":[{"name":"Clinical and Economic Studies, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Clinical and Economic Studies, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Clinical and Economic Studies, Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2020071622393866200_b1-0682265","volume-title":"Vibativ (telavancin for injection) package insert","year":"2009"},{"key":"2020071622393866200_b2-0682265","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital acquired pneumonia due to gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020071622393866200_b3-0682265","first-page":"939","article-title":"Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets","volume":"34","author":"Allen","year":"1977","journal-title":"Am J Hosp Pharm"},{"key":"2020071622393866200_b4-0682265","first-page":"2359","article-title":"Physical compatibility of melphalan with selected drugs during simulated Y-site administration","volume":"50","author":"Trissel","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"2020071622393866200_b5-0682265","first-page":"1716","article-title":"Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection","volume":"49","author":"Trissel","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"2020071622393866200_b6-0682265","first-page":"300","article-title":"Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection, part 2","volume":"50","author":"Trissel","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"2020071622393866200_b7-0682265","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ajhp\/54.11.1287","article-title":"Compatibility of propofol injectable emulsion with selected medications during simulated Y-site administration","volume":"54","author":"Trissel","year":"1997","journal-title":"Am J Health-Syst Pharm"},{"key":"2020071622393866200_b8-0682265","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2146\/ajhp080059","article-title":"Drug incompatibility chemistry","volume":"66","author":"Newton","year":"2009","journal-title":"Am J Health-Syst Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/23\/2265\/28350527\/ajhp2265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/23\/2265\/28350527\/ajhp2265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T11:06:45Z","timestamp":1594984005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/23\/2265\/5129240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":8,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100663","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,12,1]]},"published":{"date-parts":[[2011,12,1]]}}}